Bridgepoint acquiring RoC Skincare
Bridgepoint has made a strategic investment in RoC Skincare.
The skin care brand’s current backer, Gryphon Investors, will sell its majority shareholding in the company as part of the transaction.
“With Bridgepoint’s deep expertise in the dermatology sector and its strong European presence, RoC is poised to capitalise on the promising growth opportunities that lie ahead,” said Fernando Acosta, CEO of RoC Skincare. “I would like to thank the RoC team and Gryphon for their support over the past few years. Through the hard work and innovation of RoC’s talented team, we’ve become one of the largest independent skincare brands globally, while upholding our commitment to delivering the best clinically proven skin health solutions.”
[Read more: No BS Skincare launches in Walgreens nationwide]
Founded in 1957 by Dr. Jean-Charles Lissarrague in Paris, RoC Skincare offers dermatologist-backed skin health products that focus on aging skin, including broad-spectrum UV protection and retinol products sold across the United States, Canada, France, United Kingdom, Europe, Australia and China.
“Under Fernando’s leadership, RoC has become an impressive standalone business with a rich European heritage and dermatology expertise. The company’s unique, clinically proven products for ageing skin conditions are a highly appealing customer proposition with significant growth opportunities,” said Fabrice Turcq, partner at Bridgepoint. “With Bridgepoint’s support, RoC is poised to accelerate growth in Europe and beyond, strengthen its online presence and expand its product offering.”
The transaction, expected to close in February, represents the 6th acquisition by Bridgepoint’s Europe VII fund focused on investing in mid-market growth businesses.
[Read more: Perricone MD blurs pores, preps skin for makeup application]
“We are proud to have supported RoC’s growth as an independent leader in the skincare category, and grateful for the efforts of RoC’s tremendous management team,” said Matt Farron, partner at Gryphon. “We believe the Company will continue to thrive under Bridgepoint, as the Company benefits from investments in product innovation and clinical efficacy. RoC is a great example of Gryphon’s ability to use its integrated deal and operations model to build leading companies.”
